Teva will pay $25m in cash and contribute a $20m supply of an overdose-reversal drug, while AbbVie’s Allergan will pay $13m.
Teva Pharmaceutical Industries and AbbVie’s Allergan unit on Tuesday reached a $58m settlement with the United States city of San Francisco just before completion of a trial over claims that they fueled an opioid epidemic in the city.
Under the deal announced by City Attorney of San Francisco David Chiu, Israel-based Teva will pay $25m in cash and contribute a $20m supply of the overdose-reversal drug Narcan. AbbVie will pay $13m.
“This will bring significant resources to help with education, prevention and treatment, and the addition of tens of millions of dollars worth of overdose reversal medication will save lives in the Bay Area,” said Paul Geller, a lawyer who represented the city in negotiating the settlement.
Teva’s settlement also resolves the city’s claims against drug distributor Anda Inc, which is owned by Teva.
San Francisco will receive $54m, while $4m will go toward attorneys’ fees.
“Today’s settlement is another critical step forward in getting life-saving treatments to people suffering from opioid addiction,” Teva said in a statement.
AbbVie confirmed the settlement and said its discontinued branded opioid business had only a minimal market share nationwide.
The settlement was reached before closing arguments in a trial that kicked off on April 25. San Francisco will proceed with closing arguments on Tuesday against retail pharmacy chain Walgreens, the last remaining defendant in the case.
Parent company Walgreens Boots Alliance has denied doing wrong. Teva and Allergan did not admit wrongdoing as part of the settlement.
San Francisco accused Walgreens, Teva, Allergan, and Anda of creating a “public nuisance” by flooding the city with prescription opioids and failing to prevent the drugs from being diverted for illegal use.
The companies argued that they sold legal medication prescribed by doctors.
The trial was selected as a bellwether case against drug manufacturers, distributors and pharmacies, testing the strength of claims in thousands of lawsuits filed by state and local governments. In other similar trials, drugmakers also have been accused of playing down the addiction and overdose risks in marketing their painkillers.
San Francisco has been hit hard by the opioid crisis, which has caused more than 500,000 overdose deaths nationwide in the past two decades, according to US data. Opioid-related health issues account for 25 percent of emergency room visits at the city’s largest public hospital, according to a court filing at the start of the trial.
San Francisco’s lawsuit, filed in 2018, initially included claims against drugmakers Purdue Pharma LP, Johnson & Johnson and Endo International Plc, and the three largest US drug distributors – McKesson Corp, Cardinal Health Inc and AmerisourceBergen Corp.
The city settled with those defendants ahead of trial. It signed onto a $26bn nationwide settlement with Johnson & Johnson and the drug distributors, and agreed to support Purdue Pharma’s bankruptcy plan.
Teva has been attempting to reach a nationwide settlement of its opioid liability.
Teva Chief Executive Kare Schultz said on May 3 that the company expects to reach a nationwide deal by the end of 2022 and pay about $2.6bn over 15 years.